Cost-effective diagnostics for cancer? Only with VolitionRx!

biotech of the week volitionrx belgium 1213x418

Aberdeen, we say goodbye to you!

We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week.


City: Namur (Belgium)

Founded: 2010

Employees: 11-50 employees 

Financial Data: €77M

CEO: Cameron Reynolds


Mission: VolitionRx wants to address the need for non-invasive, accurate, and cost-effective diagnostics for cancer and other conditions.

Founded in 2010, VolitionRx brings together ELISA diagnostics (a long established method to identify proteins) with cutting-edge nucleosome detection and analysis techniques.

The resulting test takes less than a drop of blood and can measure and analyze nucleosomes (a basic unit of ‘packed’ DNA), which are often irregular in diseases like cancer.

Comment: The market cap of VolitionRx is over €78M, which is quite big for a diagnostics-focused biotech.

Blood-based diagnostics are a definite trend (see the discussion of Eva Diagnostics at Labiotech Refresh), and VolitionRx’s technology looks really exciting.

Feature Image Credit: Labiotech Map
Explore other topics: BelgiumCancer

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More